NCT06501378View on ClinicalTrials.gov

Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Metastasis

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

July 31, 2025

Conditions
NSCLC Stage IV
Interventions
DRUG

PD-1/PD-L1 inhibitor plus chemotherapy

Active brain metastases patients will receive PD-L1/PD-1 inhibitors and chemotherapy.

RADIATION

SRT/WBRT

Active brain metastases (BM) patients will receive stereotactic radiotherapy (SRT) and whole brain radiation therapy (WBRT) according to their BM condition.

Trial Locations (1)

Unknown

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER